Literature DB >> 11205667

Growth rate of small lung cancers detected on mass CT screening.

M Hasegawa1, S Sone, S Takashima, F Li, Z G Yang, Y Maruyama, T Watanabe.   

Abstract

CT has recently been used in mass screening for lung cancer. Small cancers have been identified but the growth characteristics of these lesions are not fully understood. We identified 82 primary cancers in our 3-year mass CT screening programme, of which 61 were examined in the present study. The volume doubling time (VDT) was calculated based on the exponential model using successive annual CT images or follow-up CT images. All cases were also examined in the hospital by high resolution CT (HRCT). Lesions were divided into three types based on HRCT characteristics: type G (n = 19), ground glass opacity (GGO); type GS (n = 19), focal GGO with a solid central component; and type S (n = 23), solid nodule. 18 (95%) lesions of type G, 18 (95%) of type GS and 7 (30%) of type S were invisible on conventional chest radiographs. The mean size of the tumour was 10 mm, 11 mm and 16 mm for type G, type GS and type S, respectively. Most tumours (80%) were adenocarcinomas; 78% of these were GGO (type G and GS). Mean VDT values were 813 days, 457 days and 149 days for type G, type GS and type S, respectively; these are significantly different from each other (p < 0.05). Our results show that annual mass screening CT for 3 successive years resulted in the identification of a large number of slowly growing adenocarcinomas that were not visible on chest radiographs.

Entities:  

Mesh:

Year:  2000        PMID: 11205667     DOI: 10.1259/bjr.73.876.11205667

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  139 in total

1.  Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility.

Authors:  Dag Wormanns; Gerhard Kohl; Ernst Klotz; Anke Marheine; Florian Beyer; Walter Heindel; Stefan Diederich
Journal:  Eur Radiol       Date:  2003-11-13       Impact factor: 5.315

2.  Evaluating the growth of pulmonary nodular ground-glass opacity on CT: comparison of volume rendering and thin slice images.

Authors:  Mingzhu Liang; Xueguo Liu; Weidong Li; Kunwei Li; Xiangmeng Chen; Guojie Wang; Kai Chen; Jinxin Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

3.  Long term follow-up for small pure ground-glass nodules: implications of determining an optimum follow-up period and high-resolution CT findings to predict the growth of nodules.

Authors:  Shotaro Takahashi; Nobuyuki Tanaka; Tomoaki Okimoto; Toshiki Tanaka; Kazuhiro Ueda; Tsuneo Matsumoto; Kazuto Ashizawa; Yoshie Kunihiro; Shoji Kido; Naofumi Matsunaga
Journal:  Jpn J Radiol       Date:  2011-12-22       Impact factor: 2.374

4.  Long-term follow-up of non-calcified pulmonary nodules (<10 mm) identified during low-dose CT screening for lung cancer.

Authors:  Michael M Slattery; Claire Foley; Dermot Kenny; Richard W Costello; P Mark Logan; Michael J Lee
Journal:  Eur Radiol       Date:  2012-04-27       Impact factor: 5.315

Review 5.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

6.  Effect of delays on survival in patients with lung cancer.

Authors:  Francisco Javier González-Barcala; José María García-Prim; José Manuel Alvarez-Dobaño; Milagros Moldes-Rodríguez; María Teresa García-Sanz; Antonio Pose-Reino; Luis Valdés-Cuadrado
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

7.  Management of subsolid pulmonary nodules in CT lung cancer screening.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

8.  Solitary pulmonary nodule: detection and management.

Authors:  S Diederich; M Das
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

9.  Contrast agents for quantitative microCT of lung tumors in mice.

Authors:  Kush Lalwani; Anand Giddabasappa; Danan Li; Peter Olson; Brett Simmons; Farbod Shojaei; Todd Van Arsdale; James Christensen; Amy Jackson-Fisher; Anthony Wong; Patrick B Lappin; Jeetendra Eswaraka
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

10.  Time to treatment in patients with stage III non-small cell lung cancer.

Authors:  Li Wang; Candace R Correa; James A Hayman; Lujun Zhao; Kemp Cease; Dean Brenner; Doug Arenberg; Jeffery Curtis; Gregory P Kalemkerian; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-21       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.